Adolescence initiates normal short stature
Conditions
Interventions
GH combined with GnRHa treatment group:NA
GH monotherapy group:NA
Sponsors
The Second Affiliated Hospital of Shantou University Medicine College
Eligibility
Sex/Gender
All
Age
9 Years to 14 Years
Inclusion criteria
Inclusion criteria: 1. Normal onset of puberty: Girls begin to develop secondary sexual characteristics after the age of 7.5, mainly manifested as breast nodules or menarche after the age of 10.0; Testicular enlargement occurs in boys after the age of 9.0; 2. If the bone age of the child exceeds the actual age by 1 year or more (i.e. BA-CA >= 1 year), according to the bone age height, the average height of normal children of the same age and gender is below -2SD (or below the 3rd percentile); If the difference between the bone age of the patient and their actual age is within ± 1 year (i.e. -1 <= BA-CA < 1 year), according to their actual age and height, they should be below -2SD (or below the 3rd percentile) of the average height of normal children of the same age and gender; 3.10 years old <= boy bone age <= 14 years old, 9 years old <= girl bone age <= 12 years old; 4. Youthful development period: Tanner stage II-III {B2-B3 stage of girls' breasts; Male testicles G2-G3 stage (testicular volume 4-15mL); 5. Uniform dwarfism with normal intellectual development 6. Chromosomes are normal; 7. The epiphysis is not closed; 8. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Cartilage dysplasia, hypothyroidism, constitutional delayed puberty, central precocious puberty, and fast progressive early development; 2. Children with chromosomal disorders, such as Prader Willi syndrome, Silver Russell syndrome, Noonan syndrome, Turner syndrome, etc; Received rhGH and GnRHa treatment within 3.6 months; 4. Children with chronic diseases or long-term use of drugs known to interfere with growth; 5. Insulin like growth factor-1 level >2SDS; 6. The epiphysis has closed; 7. Patients with contraindications for rhGH or GnRHa treatment; 8. Liver and kidney dysfunction (AST/ALT >3 times the upper limit of normal).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Predicted Adult Height (PAH); | — |
Secondary
| Measure | Time frame |
|---|---|
| Annual growth rate (GV);Height Standard Deviation Score (Ht SDS);Bone Age (BA);Insulin-like growth factor-1 Standard Deviation Score (IGF-1 SDS); | — |
Countries
China
Contacts
Public ContactHongwu Wang
The Second Affiliated Hospital of Shantou University Medicine College
Outcome results
None listed